COVID-19 Vaccination in Patients With Rheumatic Diseases (SAR-CoVAC)

Sociedad Argentina de Reumatologia

Status: Enrolling

Conditions: Rheumatic Diseases

Treatments: Biological: COVID-19 Vaccine

Study type: Observational

Funder types: Other

Identifiers

NCT04845997

02

Details and patient eligibility

About

The Argentine Society of Rheumatology (SAR) set out to develop a national register of patients with rheumatic diseases who have received a SARS-CoV-2 vaccine in order to assess their efficacy and safety in this population.

Full description

This is an observational, longitudinal, multicenter study, including patients with rheumatic diseases who have been vaccinated for COVID-19 in Argentine or any country. Patients will be followed for 12 months and two evaluations will be performed, one at baseline and the other after the follow-up time is completed.

The aim of this registry is to evaluate the efficacy and safety of the SARS-CoV-2 vaccines in patients with rheumatic diseases.

Enrollment: 3,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients ≥ 18 years of age.
• Diagnosis of rheumatic disease treated or not with immunosuppressive agents
• Patients who have received at least one dose of a SARS-CoV-2 vaccine
• Signature of informed consent.

Exclusion criteria

• Patients who express their desire not to participate in the study or who are unable to give their informed consent.